Kostine, Marie
Dousset, Léa
Schaeverbeke, Thierry
Clinical trials referenced in this document:
Documents that mention this clinical trial
Treatment-emergent antidrug antibodies related to PD-1, PD-L1, or CTLA-4 inhibitors across tumor types: a systematic review
https://doi.org/10.1136/jitc-2023-008266
Response to: ‘Checkpoint inhibitor-induced polymyalgia rheumatica controlled by cobimetinib, a MEK 1/2 inhibitor’ by Chan and Bass
https://doi.org/10.1136/annrheumdis-2018-213682
Documents that mention this clinical trial
Spartalizumab or placebo in combination with dabrafenib and trametinib in patients with <i>BRAF</i> V600-mutant melanoma: exploratory biomarker analyses from a randomized phase 3 trial (COMBI-i)
https://doi.org/10.1136/jitc-2021-004226
Update on BRAF and MEK inhibition for treatment of melanoma in metastatic, unresectable, and adjuvant settings
https://doi.org/10.1080/14740338.2019.1607289
Efficacy of nivolumab plus relatlimab versus BRAF/MEK inhibitors for first-line treatment of
<i>BRAF</i>
-mutant advanced melanoma: A matching-adjusted indirect comparison
https://doi.org/10.1136/bmjonc-2025-000912
Response to: ‘Checkpoint inhibitor-induced polymyalgia rheumatica controlled by cobimetinib, a MEK 1/2 inhibitor’ by Chan and Bass
https://doi.org/10.1136/annrheumdis-2018-213682
Evolving impact of long-term survival results on metastatic melanoma treatment
https://doi.org/10.1136/jitc-2020-000948
307 Atezolizumab plus vemurafenib and cobimetinib provides favorable survival outcomes in patients with high tumor mutation burden and proinflammatory gene signature in the phase 3 IMspire150 study
https://doi.org/10.1136/jitc-2020-sitc2020.0307
301 Association of response with survival outcomes with atezolizumab in combination with vemurafenib and cobimetinib in the phase 3 IMspire150 study
https://doi.org/10.1136/jitc-2020-sitc2020.0301
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of melanoma, version 3.0
https://doi.org/10.1136/jitc-2023-006947
Documents that mention this clinical trial
Spartalizumab or placebo in combination with dabrafenib and trametinib in patients with <i>BRAF</i> V600-mutant melanoma: exploratory biomarker analyses from a randomized phase 3 trial (COMBI-i)
https://doi.org/10.1136/jitc-2021-004226
Update on BRAF and MEK inhibition for treatment of melanoma in metastatic, unresectable, and adjuvant settings
https://doi.org/10.1080/14740338.2019.1607289
Response to: ‘Checkpoint inhibitor-induced polymyalgia rheumatica controlled by cobimetinib, a MEK 1/2 inhibitor’ by Chan and Bass
https://doi.org/10.1136/annrheumdis-2018-213682
KEYNOTE-022 part 3: a randomized, double-blind, phase 2 study of pembrolizumab, dabrafenib, and trametinib in <i>BRAF</i>-mutant melanoma
https://doi.org/10.1136/jitc-2020-001806
P863 KEYNOTE-022 parts 4 and 5: pembrolizumab plus trametinib for patients with solid tumors or BRAF wild-type melanoma
https://doi.org/10.1136/lba2019.16
Documents that mention this clinical trial
Response to: ‘Checkpoint inhibitor-induced polymyalgia rheumatica controlled by cobimetinib, a MEK 1/2 inhibitor’ by Chan and Bass
https://doi.org/10.1136/annrheumdis-2018-213682
A randomized phase 2 study of combination atezolizumab and varlilumab (CDX-1127) with or without addition of cobimetinib in previously treated unresectable biliary tract cancer.
https://doi.org/10.1200/jco.2024.42.16_suppl.4017
This article is maintained by: Elsevier
Article Title: Response to: ‘Checkpoint inhibitor-induced polymyalgia rheumatica controlled by cobimetinib, a MEK 1/2 inhibitor’ by Chan and Bass
Journal Title: Annals of the Rheumatic Diseases
CrossRef DOI link to publisher maintained version: https://doi.org/10.1136/annrheumdis-2018-213682
CrossRef DOI link to the associated document: https://doi.org/10.1136/annrheumdis-2018-213672
Content Type: simple-article
Copyright: Copyright © 2019 © Author(s) (or their employer(s)) 2019. No commercial re-use. See rights and permissions. Published by Elsevier Inc. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.